PERMANENT AWARD EVIDENCE
NHS England · published 21 Jan 2025. This page preserves the identifiers and current held fields for one Contracts Finder release; it is not an invoice, performance assessment or complete contract history.
ffeee3ac-9be3-4ea0-8c54-091ab8be7d3f-819135ocds-b5fd17-e85a5f73-1208-4e45-a159-08011aef8a18GB-CFS-298819A tender estimate and an award value answer different questions. Neither is treated as cash paid.
Project title: NHS National Framework for Transition products commencing 1 February 2025 Offer reference number: CM/TNS/24/5713 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5713/01 - Eribulin Injection, Bosutinib Tablets and Liraglutide Injection Lot 1 CESW: 01/02/2025 to 31/05/2026 (16 months) Lot 2 LSNE: 01/02/2025 to 31/05/2026 (16 months) Lot 3 NWLN: 01/02/2025 to 31/05/2026 (16 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
The current projection contains one award release, not a verified chain of planning, tender, award, contract and modification records. Dates are shown in source-field order and are not silently repaired.
A company profile appears only when this release carries a usable company number. Name-only suppliers remain name-only.
No legal entity is inferred from this supplier name.
No legal entity is inferred from this supplier name.
No legal entity is inferred from this supplier name.
No legal entity is inferred from this supplier name.
No legal entity is inferred from this supplier name.
No legal entity is inferred from this supplier name.
Published 21 Jan 2025 · held through the daily award projection · Open Government Licence v3.0.